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Abstract 
Mendelian causes of inherited cancer susceptibility are mostly rare and characterized by variable 
expression and incomplete penetrance. Phenotypic variability may result from a range of causes 
including locus heterogeneity, allelic heterogeneity, genetic and environmental modifier effects or 
chance. Another potential cause is the presence of two or more inherited cancer predisposition 
alleles in the same individual. Though the frequency of such occurrences might be predicted to be 
low, such cases have probably been under ascertained because standard clinical practice has 
been to test candidate inherited cancer genes sequentially until a pathogenic mutation is detected. 
However, recent advances in next generation sequencing technologies now provide the 
opportunity to perform simultaneous parallel testing of large numbers of inherited cancer genes. 
Here we provide examples of patients who harbor pathogenic mutations in multiple inherited 
cancer genes and review previously published examples to illustrate the complex genotype-
phenotype relationships in these cases. We suggest that clinicians should proactively consider the 
likelihood of this phenomenon (referred to here as Multilocus Inherited Neoplasia Alleles Syndrome 
(MINAS)) in patients with unusual inherited cancer syndrome phenotypes. To facilitate the clinical 
management of novel cases of MINAS we have established a database to collect information on 
what is likely to be an increasingly recognized cohort of such individuals.      
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Introduction 
In clinical practice the maxim of Occum’s razor is often adopted1 such that, whenever possible, a 
single diagnosis is favored over multiple diagnoses. Rare diseases have a frequency of less than 1 
in 20002 and statistically the chances of an individual being affected by two or more rare diseases 
would appear to be remote. However, with more than 6,000 rare diseases and up to 6-8% of the 
European population estimated to suffer from a rare disease at some time in their lifetime2, there is 
potential for two or more rare disorders to occur by chance.This  scenario has been reported in 
various constitutional disorders with both distinct and overlapping phenotypes, including familial 
neoplasia and/or patients with multiple primary tumors. If Occum’s razor is applied then the 
detection of a mutation in a specific inherited cancer gene might lead the clinician to attribute any 
tumors that are not typical features of the relevant inherited cancer syndrome to examples of 
variable phenotypic expression or coincidence. In such circumstances the patient may receive 
suboptimal management and the estimated cancer risks to relatives could be erroneous. In 
addition, studies of patients harboring multiple mutations in different familial cancer syndrome 
genes could provide insights into how the function of the relevant gene products may be related 
e.g. if a particular combination resulted in a more pronounced or novel phenotype (analogous to 
the differences in phenotype between patients with monoallelic and biallelic mismatch repair 
(MMR) gene mutations3).The best known examples of patients with multiple inherited cancer gene 
mutations are reports of patients with mutations in BRCA1 and BRCA24–22. Interestingly, the 
phenotype in these patients has generally not been shown to be more severe than when a single 
mutation is present.  
 
Here we report five new cases with multiple pathogenic germline mutations in rare inherited cancer 
syndrome genes. Three involve the combination of mutations in FLCN with NF1, TP53 and MSH2 
respectively, one in MLH1 and XPA and the fifth in NF1 and BRCA2. In addition, we reviewed the 
published literature to identify other cases and provide a summary of the published experience to 
date. We suggest that this phenomenon will be increasingly recognized and careful descriptions of 
such cases will inform the management of similar patients. 
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Case Reports 
Case 1:  
A 39 year old man presented with testicular seminoma and a routine abdominal scan four years 
later revealed a pheochromocytoma. Following his seminoma diagnosis he also developed a 
pneumothorax and went on to have six further occurrences. At age 55 years he complained of 
abdominal/ back pain and a CT scan revealed bilateral renal masses that were demonstrated to be 
renal cell carcinomas (RCC) following removal. Reinvestigation following further episodes of 
abdominal pain identified two gastrointestinal stromal tumors (GIST). At age 56 years, a CT lung 
scan (to investigate a pneumothorax) revealed a malignant peripheral nerve sheath tumour 
(MPNT). Skin examination revealed multiple skin neurofibromas, two café au lait patches and 
axillary frecklingbut no fibrofolliculomas. A clinical diagnosis of neurofibromatosis type1 (NF1) was 
made and though this was considered to be the cause of his MPNT and possibly 
pheochromocytoma and GIST, the history of renal cancers and recurrent pneumothorax were 
considered unrelated.  
 
Next generation sequencing (NGS) of 94 inherited cancer genes was performed using the Illumina 
TruSight cancer panel23. A previously reported splice site mutation in FLCN (c.1062+2T>G)24,25 
and a nonsense mutation in NF1 (c.1381C>T p.(Arg461*)) were detected and confirmed by Sanger 
sequencing. FLCN mutations cause Birt-Hogg-Dube syndrome (BHD), a rare condition where 
affected individuals are predisposed to RCC, pulmonary cysts and pneumothoraces and 
fibrofolliculomas. A first degree relative had also been diagnosed with bilateral chromophobe RCCs 
at age 45 years and was found to have facial fibrofolliculomas though did not have genetic testing. 
Presence of the FLCN mutation was demonstrated in a further first and second degree relative but 
both were asymptomatic with normal renal scans. It was also identified in a second degree relative 
with numerous fibrofolliculomas and a history of recurrent pneumothorax (x2). An obligate carrier in 
the family had pancreatic adenocarcinoma but was not known to have features of BHD syndrome 
during life, although autopsy revealed bilateral renal oncocytomas. There was no known family 
history of NF1. 
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NF1 has a population frequency of 23/100.00026 and might be expected to exist in combination 
with another inherited cancer syndrome relatively rarely, though phenotypic variability and use of 
clinical diagnostic criteria (rather than genetic testing) may underestimate this. It is associated with 
predisposition to a variety of neoplasms including pheochromocytoma, GIST, carcinoid tumour, 
cutaneous/plexiform neurofibromas and MPNT. Thus in this case associated with two pathogenic 
inherited cancer syndrome gene mutations, the occurrence of the MPNT, phaeochromocytoma, 
GIST and RCC can be explained but testicular seminoma has not been associated with mutations 
in either gene27,28. This suggests that the seminoma might be a consequence of the combination of 
FLCN and NF1 mutations (seminoma has been linked to aberrations in the c-kit, RAS/MAPK and 
PI3K/AkT pathways29 and the NF1 and FLCN gene products regulate RAS/MAPK and 
mTOR/PI3K/Akt signaling respectively29,30) or be coincidental,testicular the most common male 
solid tumour in the 15-34 age group31.  
 
Case 2: 
A 32 year old man presented with dysphagia. There was a previous history of ulcerative colitis for 
which he had undergone a pan-protocolectomy at age 27 years and pathological examination of 
the colectomy specimen had revealed an incidental rectal adenocarcinoma. Endoscopy revealed a 
gastroesophageal junction adenocarcinoma and staging imaging demonstrated a 6cm left kidney 
tumor. Biopsy of the latter suggested a primary renal neoplasm, prompting nephrectomy. Histology 
of the resected kidney confirmed a chromophobe RCC. Examination of the skin showed facial 
fibrofolliculomas. There was no history of cancer in first degree relatives but tumours in second 
degree relatives included oesophageal squamous cell carcinoma at age 54 years , a brain tumor of 
uncertain histology at age 50 and an oropharyngeal carcinoma at 49 years.  
 
Genetic investigations revealed two pathogenic mutations in FLCN (c.715C>T p.(Arg239Cys))32 
and TP53 (c.526T>C p.(Cys176Arg)). The latter has been reported as a somatic mutation on 
multiple occasions33,34, including in colorectal adenocarcinoma33 but not previously in germline 
samples34. It is rare and does not appear in the ExAC dataset35. In silico tools predict a damaging 
or function altering effect36–38. No other family members were available for genetic testing. 
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Kidney tumors, typically with a hybrid chromophobe/oncocytic RCC histopathology, are a major 
feature of BHD syndrome. RCC has been reported in TP53 mutation carriers though no firm 
association been made39. The relationship between colorectal cancer and BHD syndrome is 
controversial24,40 but an increased risk of colorectal cancer has been reported with ulcerative colitis 
(though typically in those with disease for >10 years41) and also in TP53 mutation carriers. To our 
knowledge, esophageal cancers have not been reported in FLCN mutation carriers but have 
occurred in Li-Fraumeni syndrome (LFS) families, though again the association with this condition 
is not clear39,42. We note that the median age at diagnosis of renal tumors in FLCN mutation 
carriers (48 years)25 is older than the age at onset of these tumors in this case. 
 
Case 3: 
A 53 year old woman presented with a rectal adenocarcinoma and had a history of spontaneous 
pneumothorax at age 46 years. . Immunohistochemistry performed on the proband’s rectal tumour 
showed no abnormality but a relative’s (who also had multiple pneumothoraces) colon cancer 
demonstrated loss of staining of MSH2 and MSH6 proteins. Germline genetic testing in the 
proband did not detect a pathogenic mismatch repair gene mutation but a pathogenic FLCN 
mutation (c.1285delC p.(His429Thrfs*39)) was identified. Three siblings had phenotypic similarities 
to the proband. A sister developed a pneumothorax at age 37 and had facial fibrofolliculomas. She 
developed endometrial cancer at 52 years. Genetic testing demonstrated the familial FLCN 
mutation and a MSH2 truncating mutation (c.892C>T p.(Gln298*)). The twin sister of this individual 
had pneumothoraces, RCC and colorectal polyps. She also carried both mutations, as did a 
brother with facial fibrofolliculomas.  
 
Colorectal and endometrial cancers are characteristic of Lynch syndrome caused by MSH2 
mutations and the ages of diagnosis seen in this family are typical43. However, the proband did not 
carry the pathogenic MSH2 mutation detected in her siblings and may represent a phenocopy. 
Also, a role of the FLCN mutation in the development of colorectal tumours in the family cannot be 
excluded24,40. Fibrofolliculomas, RCC and pneumothoraces are not associated with Lynch 
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syndrome44.  
 
Case 4: 
A male proband presented with a mucinous caecal cancer at age 65 years and a metachronous 
sigmoid colon cancer in his remaining large bowel at 67 years. One first degree relativehad 
developed colon cancer at age 42, but there was no other family history of Lynch syndrome-related 
tumours.  His parents were not knowingly consanguineous, but were both from the same small 
community in India. The proband had been clinically diagnosed in early childhood with xeroderma 
pigmentosum (XP).  At least one other first degree relative was known to have a similar pattern of 
skin tumours, but that individual had no internal malignancies.  Neither parent had any reported 
skin abnormalities.  On examination his sun-exposed skin showed considerable signs of ultraviolet 
damage (e.g. severe freckling and loss of pigment) but no other features of XP such as 
neurological or intellectual deficits.  His skin tumours over the previous 20 years had included a 
squamous carcinoma in an actinic keratosis, several seborrheic keratoses, two 
keratoacanthomata/squamous carcinomas, junctional nevi, a squamous carcinoma and two lentigo 
malignae (premalignant melanoma).  Immunohistochemistry demonstrated loss of MLH1 and 
PMS2 expression in both colon cancers.  Constitutional genetic testing revealed MLH1 c.306G>T 
p.(Glu102Asp) (classed as likely pathogenic45).  Fibroblasts from a skin biopsy were tested for XP, 
which showed reduced levels of nucleotide excision repair. He therefore did not have mild XP 
variant (XP-V) as might be expected, but rather had mild variant XP-A, consistent with survival into 
his 60s.  Constitutional genetics analysis revealed a homozygous XPA intron 4 splice mutation 
(c.555+8A>G). Molecular analysis of his various tumours is summarised in Table 1.  
 
The prevalence of microsatellite instability (MSI) in skin tumours in XP is unknown. A contribution 
of the MLH1 mutation to the dermatological phenotype may be suggested by its presence in some 
of the skin tumours but the presence of normal MLH1 and PMS2 expression goes against this.  
Skin tumours are associated with Lynch syndrome but these are characteristically sebaceous in 
origin, which were not observed in this case. 
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Case 5: 
A female patient with NF1, having one café au lait patch, numerous cutaneous neurofibromas, 
possible Lisch nodules and a MPNT, was diagnosed with a ductal breast carcinoma at age 48 
years and subsequently went on to develop a cutaneous melanoma at age 57 years.  
Constitutional genetic testing revealed both NF1 c.6792C>G p.(Tyr2264*) and BRCA2 
c.5213_5216del p.(Thr1738Ilefs*2)46. Mutations in both genes can be associated with breast 
cancer47 but the risk is much higher for BRCA2. The breast cancer could be consistent with either 
syndrome and no tumor analysis was reported that could help determine which gene was more 
significant in its initiation. 
 
Having identified five cases harbouring multilocus inherited neoplasia gene mutations we 
proceeded to review the published literature to determine the nature and frequency of similar cases 
in a systematic fashion. We propose the term “Multilocus Inherited Neoplasia Alleles Syndrome” 
(MINAS) to describe this phenomenon.  
 
Literature Survey of Multilocus Inherited Neoplasia Alleles Syndrome  
Identification of cases 
To review published cases with MINAS we undertook a systematic review of the published 
literature (see Supplementary Methodology section) based on a list of inherited cancer genes 
(n=94) (Supplementary Table 1).  
 
Clinical Aspects 
82 cases involving 17 inherited cancer genes were identified4–7,20,48–69 (see Supplementary Table 
2). The combination of co-existing mutations in BRCA1/BRCA2, BRCA2/TP53, BRCA1/MLH1 and 
APC/MLH1 were the only combinations that occurred in more than one family. This may reflect 
ascertainment bias (certain genes are commonly screened for simultaneously), common founder 
mutations present in specific populations and hereditary breast cancer, followed by colorectal 
cancer, being the most common indication for cancer genetic assessment70. Indeed, 13 patients 
had a combination of two of the three Ashkenazi founder BRCA1 and BRCA2 mutations.  
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An interesting aspect of patients with MINAS is whether mutations in particular combinations of 
genes are associated with a more (or less) severe phenotype (e.g. earlier onset of cancer or 
cancer types not usually seen in individuals with a single mutation). The wide variety of 
combinations of individual germline mutations means that, with the exception of BRCA1/BRCA2, 
mutation combinations the information on phenotypic effects is limited.   
 
Leegte et al8 described 12 cases of combined BRCA1/BRCA2 mutation cases and suggested that 
there was no evidence of increased severity whereas Heidemann et al7 reported eight cases and 
suggested that a more severe phenotype was observed in two. Other combinations of inherited 
breast cancer genes have been described. For example, a combination of mutations in BRCA1 
and PALB2 was described in a patient with multifocal breast cancer67 (Case 25, Supplementary 
Table 2). Uterine leiomyomas and a meningioma were also diagnosed but it is impossible to know 
whether these were related to a specific mutations or were coincidental.  
Two reports of germline BRCA2 and TP53 mutations were identified53,54. In a mouse model where 
the homologues of both of these genes are conditionally knocked out in epithelial tissues (to avoid 
embryonic lethality), a greater incidence and earlier onset of mammary and skin carcinomas was 
observed in comparison to mice where only Trp53 or Brca2 was conditionally knocked out (with 
conditional knockout/wild type heterozygosity in the other gene), suggesting a synergistic effect in 
these tissues72. Though the mouse model is not directly comparable to the human status, more 
than two cancers had occurred in both cases of BRCA2/TP53 MINAS, ,though one tumor was 
within the radiotherapy field and the ages of diagnosis in these cases are not atypical for mutations 
in either gene39,73.  
 
The second most frequently reported examples of specific MINAS were combinations of genes 
predisposing to inherited colorectal cancers62–66 (cases 20-24, Supplementary Table 2). 
Interestingly, severe phenotypes were noted in two patients with APC/MLH1 mutation 
combinations with jejunal cancer seen in one case62 and accelerated polyp progression in the 
other65.  
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The phenotypic consequences of MINAS may be easier to interpret when the two genes involved 
are associated with dissimilar and narrow phenotypes. Thus, there are various reports of a 
BRCA1/BRCA2 mutation in combination with a mismatch repair gene mutation (see cases 1-4, 
Supplementary Table 2). In general these have not demonstrated clear evidence of a synergistic 
effect of these types of mutations on the severity of the phenotype although one reported case with 
BRCA1 and MLH1 mutations had a severe phenotype involving early onset bilateral breast cancer, 
and endometrial, ovarian and clear cell renal cancers diagnosed at age 39 years. Both breast 
tumors showed loss of the wild-type BRCA1 allele but also showed absent staining of MLH1 on 
immunohistochemistry and loss of the wild-type MLH1 allele. This suggests that both germline 
mutations were significant in breast tumorigenesis in this patient. The high number of tumors and 
the development of early onset RCC (not usually associated with BRCA1 or MLH1 mutations) 
suggests a possible synergistic effect49.   
 
Reports of other MINAS cases with specific gene combinations are rare. For example PTEN 
mutations, which affect the PI3K/Akt signaling pathway74,75 are reported in combination with 
mutations in TP5359, APC60 and SDHC61 with tumors characteristic of each mutation being 
observed in all three cases. A number of the tumors in the PTEN/TP53 case were not typical of a 
mutation in either gene and early onset of colonic polyps and paraganglioma were noted in the 
other patients. PTEN normally acts via Akt to down regulate MDM2 (and therefore increase p53 
levels) in addition to its other roles74,75 so this interaction may lead to a more severe phenotype.  
A further case of BRCA1 and NF1 mutations in a patient with cutaneous features of NF1 and early 
onset (age 35) breast cancer has also been described69. Of note is the fact that NF1 and BRCA1 
are both located on the long arm of chromosome 17. The presence of early onset breast cancer 
and NF1 in the patient’s mother along with both mutations being found in the proband may suggest 
that the two altered genes were in cis. Such information has significant implications for genetic 
counselling of families where multiple mutations are identified though interestingly, the probands 
brother, who also had NF1, did not carry the BRCA1 mutation suggesting a recombination event in 
the mother.  
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A case of MINAS involving a FLCN and APC mutations has been reported56. Typical colonic polyps 
and a colorectal cancer at age 28 occurred, as well as recurrent pneumothoraces and facial 
papules. The features are consistent with an independent mechanism, though the authors 
suggested that the FLCN mutation might have enhanced the tumorigenic process given the 
observation that somatic FLCN mutations frequently occur in (microsatellite unstable) colorectal 
cancers40.  
 
Molecular Genetics Aspects 
In theory, insights into the role of individual inherited cancer gene mutations in the pathogenesis of 
tumor types that are rarely associated with either of the relevant genes (or tumor types associated 
with both genes) might be derived from loss of heterozygosity (LOH) studies (assuming the 
relevant inherited cancer genes are tumor suppressor genes (TSGs)). LOH analysis, however, can 
be uninformative if the somatic mutation (“second hit”) is a point mutation or promoter methylation 
of the wild-type allele (i.e. no LOH)5). For example, LOH analysis of three primary breast cancers 
from a woman with BRCA1/BRCA2 MINAS demonstrated LOH at BRCA1 in one tumor and at 
BRCA2 in the other two- suggesting that there was no direct interaction between the two loci in the 
tumors. However, in another case report of BRCA1/BRCA2 MINAS, LOH at both loci was 
demonstrated in an ovarian cancer from the same patient19.  
 
Future Perspectives 
There are inherent ascertainment biases influencing which MINAS cases are present in the 
literature including more frequent analysis of combinations of particular genes, the range of 
phenotypes referred for testing and the restriction of analyzed genes to only those most strongly 
suggested by the tumor history. Availability, or lack thereof, of analysis of certain genes in some 
centers may also be a factor and is likely to have led to recognition of three FLCN MINAS cases at 
our center where this gene is tested frequently. Clinical features as the skin manifestations of BHD 
syndrome and NF1 can indicate the need for analysis of specific genes but increasing use of 
cancer gene panels or whole exome/genome sequencing provides the opportunity for a more 
comprehensive genetic testing strategy and is likely to result in increased recognition of cases of 
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MINAS. Increasing detection will inevitably lead to increased demand for accurate information on 
whether particular combinations of mutations are likely to result in a particularly severe phenotype 
(i.e. a synergistic interaction) or whether the resulting phenotype is typical of each mutation having 
an independent effect. Review of previous reports of MINAS reveals that although a more severe 
phenotype seems likely in some cases, this cannot be concluded in the majority. In utero death 
from more severe manifestations of mutation combinations may account for some milder 
phenotypes but where survival occurs, MINAS may be more likely suspected in severe cases or 
those with an atypical phenotype. We suggest that as further cases are uncovered by routine 
multigene testing strategies, those cases with a less severe phenotype will be recognized more 
easily. However, in certain circumstances it may be prudent to expect that a particular combination 
of mutations might result in a more severe phenotype. Thus, if an individual has mutations in TSGs 
that map to the same chromosome region, loss of a chromosome (or part of) harboring the wild 
type alleles will result in a tumor homozygous null for both TSGs (this may have occurred in Case 
2 as FLCN and TP53 map to 17p11.2 and 17p13.1 respectively). Also if there is a direct 
relationship between the mechanisms of tumorigenesis of the two mutations (e.g. APC and 
mismatch repair gene mutations) a more severe phenotype may occur. In addition, two gain-of-
function mutations in proto-oncogenes might predict a more severe phenotype (though we have 
not found reports of such cases) because, in contrast to TSGs, an additional event (somatic 
inactivation of a wild-type allele) is not required to initiate tumorigenesis. As mutation-dependent 
targeted therapies for the treatment of cancers become a more common option in oncology, the 
recognition of MINAS and application of tumor analysis to define the most likely driver mutation will 
become more important.  
 
The optimum resource with which to discern the effects of individually rare mutation combinations 
and improve future management of patients with MINAS is a reference database containing 
clinical, genetic and tumor information. Such information could guide the clinician as to what the 
effect of each combination of mutations might be. To facilitate sharing of such information, cases 
can be uploaded to the Leiden Open Variant Database and identified by “MINAS” phenotype 
(http://databases.lovd.nl/shared/diseases/04296). We hope that other oncology and genetics heath 
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care professionals and researchers will contribute their cases in order to increase knowledge of 
this emerging phenomenon.  
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Table 1:  Molecular analysis of tumors from Case 4 
 
 
Tumour MLH1 IHC PMS2 IHC MSI assessment 
Mucinous caecal adenocarcinoma Loss Loss High 
Sigmoid colon adenocarcinoma Loss Loss High 
Squamous carcinoma (#1) Present Present Stable 
Squamous carcinoma (#2) Present Present Stable 
Lentigo maligna Present Present High 
Actinic keratosis Present Present High 
Squamous carcinoma in actinic 
keratosis  Present Present High 
 
Key: 
MSI - Microsatellite instability. IHC - Immunohistochemistry 
 
 
